Watson buys women's health-focused Uteron for up to $305m as it adopts Actavis name
This article was originally published in Scrip
On the eve of Watson Pharmaceuticals' transition to a new name in honor of the company's $5.6 billion acquisition of global generics competitor Actavis in 2012, the US firm has announced a purchase worth up to $305 million that's meant to fill its brand-name drug pipeline and increase the company's presence in the women's health market.
You may also be interested in...
Emerging Company Profile: Medicines360 and partner Allergan launched the IUD Liletta in 2015, so now the nonprofit pharmaceutical company is looking for additional contraceptives and women’s health products.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.